A fully automated, AI-powered solution for assessment of solid tumors

Given Brainomix's success in developing imaging biomarkers for Stroke and Interstitial Lung Disease (ILD), future research and development will expand the Brainomix 360 platform to include a Cancer solution, with a focus on improving treatment response assessment in Oncology.

Brainomix’s Cancer solution has been trained to characterize and quantify solid-tumors using thousands of cases from leading academic institutions, unlocking objective measurement of tumor lengths, and other biomarkers such as tumor volume.

AI-powered biomarkers from Brainomix's Cancer solution are available now for use in clinical trials, and can support:

Efficacy detection, as an adjunct to traditional human-derived measures such as RECIST

Blinded Independent Central Review (BICR) with AI-powered objectivity and standardization

Objective assessment and comparison of early-stage treatments

Reduced sample sizes and faster trial execution

Contact Us Today

Speak with us to learn how to integrate our oncology biomarkers into your clinical trials and clinical research.

*Mandatory field

I have read the Brainomix privacy policy

I would like to receive information about products or services from Brainomix

Hear from our valued partners and collaborators

Semmelweis Clinic

Budapest, Hungary

"Both thrombolysis and thrombectomy rates increased once e-Stroke was installed.."

Heidelberg University Hospital

Germany

"e-Stroke provides our team with the most complete AI-powered imaging application for NCCT in the AIS pathway."

Klinikum Braunschweig

Braunschweig, Germany

"With Brainomix software we are faster, better and safer."

Our Partners